Ebruba E. Oyekan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ebruba E. Oyekan has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Aisha Hameed
Obstetrics and Gynaecology Division of Women’s Health, Princess Royal University Hospital, Kings College Hospital NHS Foundation Trust, London SE5 9RS, UK
1 shared publication - Anita Banerjee
Department of Diabetes and Endocrinology Guy's and St Thomas' NHS Foundation Trust London UK
1 shared publication - Caroline Ovadia
Department of Women and Children's Health, King's College London, London, UK; Centre for Reproductive Health, Institute for Regeneration and Repair, University of Edinburgh, Edinburgh, UK
1 shared publication - Doaa Ahmed
Women’s Services, Guys’ and St Thomas’ NHS Foundation Trust, London SE1 9RT, UK
1 shared publication - Hannah L. Nathan
MRCOG PhD, Obstetric Registrar, Department of Obstetrics, Lewisham and Greenwich NHS Foundation Trust, London, UK
1 shared publication - Katherine Pacifico
Women’s Services, Guys’ and St Thomas’ NHS Foundation Trust, London SE1 9RT, UK
1 shared publication
Latest Publications
- Open Access
- 30 May 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (6) , 223
Developing a Risk Stratification Tool to Predict Patients with Gestational Diabetes Mellitus at Risk of Insulin Treatment: A Cohort Study
Objectives: We aimed to develop and validate a simple, easy-to-use risk stratification tool to use in the diagnosis of gestational diabetes mellitus (GDM) to triage those more likely to require insulin treatment. Methods: Using an audit of patients with GDM in 2019, multivariable logistic regression was used to select variables and develop a prediction model for insulin requirement. A stratification tool was developed by dichotomising these selected variables; its performance was assessed with an internal cohort from 2021 and externally from patients managed at a separate hospital. Results: Patients with a higher fasting blood glucose concentration (OR 2.41, 95% CI 1.84–3.15) and higher booking body mass index (OR 1.48, 95% CI 1.07–2.03) were more likely to require insulin therapy whilst a later gestational-weeks-at-diagnosis value gave a lower risk of insulin therapy (OR 0.71, 95% CI 0.62–0.81 per week). The low-risk group for insulin requirement was defined thus: fasting blood glucose < 5.6 mmol/L, booking BMI < 30 kg/m2, and gestational weeks at diagnosis ≥ 24 weeks. This classification had a negative predictive value (NPV) of 94% for insulin requirement, with a sensitivity of 84% and specificity of 56% in the development cohort. Similarly, in the internal and external validation cohorts, the NPVs were 93 and 90%, with sensitivity values of 77 and 78%, respectively. Conclusions: This study developed a pragmatic tool with three criteria for stratifying the GDM group not requiring insulin treatment, with successful validation for clinical use.
- 30 May 2025
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (6) , 223
Open AccessDeveloping a Risk Stratification Tool to Predict Patients with Gestational Diabetes Mellitus at Risk of Insulin Treatment: A Cohort Study
Objectives: We aimed to develop and validate a simple, easy-to-use risk stratification tool to use in the diagnosis of gestational diabetes mellitus (GDM) to triage those more likely to require insulin treatment. Methods: Using an audit of patients with GDM in 2019, multivariable logistic regression was used to select variables and develop a prediction model for insulin requirement. A stratification tool was developed by dichotomising these selected variables; its performance was assessed with an internal cohort from 2021 and externally from patients managed at a separate hospital. Results: Patients with a higher fasting blood glucose concentration (OR 2.41, 95% CI 1.84–3.15) and higher booking body mass index (OR 1.48, 95% CI 1.07–2.03) were more likely to require insulin therapy whilst a later gestational-weeks-at-diagnosis value gave a lower risk of insulin therapy (OR 0.71, 95% CI 0.62–0.81 per week). The low-risk group for insulin requirement was defined thus: fasting blood glucose < 5.6 mmol/L, booking BMI < 30 kg/m2, and gestational weeks at diagnosis ≥ 24 weeks. This classification had a negative predictive value (NPV) of 94% for insulin requirement, with a sensitivity of 84% and specificity of 56% in the development cohort. Similarly, in the internal and external validation cohorts, the NPVs were 93 and 90%, with sensitivity values of 77 and 78%, respectively. Conclusions: This study developed a pragmatic tool with three criteria for stratifying the GDM group not requiring insulin treatment, with successful validation for clinical use.